Close Menu

Takara Bio

WaferGen Biosystems and collaborators in the laboratory of Jo Vandesompele at the University of Ghent have developed a PCR-based target enrichment workflow using WaferGen's SmartChip real-time PCR system, the company said this week.

Quest Diagnostics has been awarded US Patent No. 8,346,485, "Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction."

NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said it has licensed a patent from Takara Bio for detecting internal tandem duplication mutations in the FLT3 gene.

NEW YORK (GenomeWeb News) – Takara Bio said Monday that it has signed an agreement to offer Pathogenica's HAI BioDetection Kit in Japan as part of its sequencing services.

NEW YORK (GenomeWeb News) – WaferGen Bio-system's third-quarter revenues almost doubled year over year, the company said in its quarterly earnings document filed with the US Securities and Exchange Commission on Friday.

NEW YORK (GenomeWeb News) – WaferGen Bio-systems said today it has acquired an exclusive license to a patent covering a novel RNA Quality Control technology.

NEW YORK (GenomeWeb News) – Takara Bio will distribute Exiqon's miRCURY LNA products in Asia beginning in January 2013, Exiqon announced today.

WaferGen Biosystems said this week that it has been awarded a €1 million ($1.3 million) matching grant by the Luxembourg government to help it expand its European operations, which are headquartered in Luxembourg.

NEW YORK (GenomeWeb News) – WaferGen Biosystems has received a €1 million ($1.3 million) matching grant from the Luxembourg government to expand its European operations, the company announced after the close of the market on Tuesday.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.